natgillin/translations-raw huggingface dataset:
The summary of the opinion of the Committee for Orphan Medicinal Products for Prevymis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Prevymis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
What are the risks associated with Prevymis? 
Kakšna tveganja so povezana z zdravilom Prevymis?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Prevymis have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Prevymis upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Why is Prevymis approved? 
Zakaj je bilo zdravilo Prevymis odobreno?
This is a summary of the European public assessment report (EPAR) for Prevymis. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Prevymis.
For more information about treatment with Prevymis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Prevymis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Prevymis 
Druge informacije o zdravilu Prevymis
Of the patients receiving Prevymis, about 38% (122 out of 325) had signs of CMV becoming active 24 weeks after the stem cell transplant compared with 61% of the patients (103 out of 170) receiving placebo. 
Znake citomegalovirusa, ki se je aktiviral 24 tednov po presaditvi matičnih celic, je imelo 38 % (122 od 325) bolnikov, ki so prejemali zdravilo Prevymis, v primerjavi z 61 % bolnikov (103 od 170), ki so prejemali placebo.
For CMV to multiply, its genetic material (DNA) needs to be copied and packaged into protein shells to produce more viruses that can then infect other cells. 
Da se citomegalovirus lahko razmnožuje, se mora njegov genetski material (DNK) kopirati in nalagati v beljakovinske ovojnice, da nastane več virusov, ki lahko nato okužijo druge celice.
The full EPAR for Prevymis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Prevymis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Terminase is involved in packaging the DNA in the protein shells of the virus. 
Terminaza je udeležena pri ovijanju DNK v beljakovinske ovojnice virusa.
The most common side effects with Prevymis (which may affect up to 1 in 10 people) are nausea (feeling sick), diarrhoea and vomiting. 
Najpogostejši neželeni učinki zdravila Prevymis (ki se lahko pojavijo pri največ 1 bolniku od 10) so navzeja (slabost), driska in bruhanje.
Doctors should consider official guidance on the use of antiviral medicines when using Prevymis. 
Zdravniki morajo pri uporabi zdravila Prevymis upoštevati uradne smernice za uporabo protivirusnih zdravil.
Because the number of patients with CMV disease is low, the disease is considered ‘rare', and Prevymis was designated an ‘orphan medicine' (a medicine used in rare diseases) on 15 April 2011. 
Ker je bolnikov z obolenjem zaradi okužbe s citomegalovirusom malo, velja ta bolezen za redko, zato je bilo zdravilo Prevymis 15. aprila 2011 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
The combination of Prevymis and ciclosporin must not be used with dabigatran, atorvastatin, pitavastatin, rosuvastatin and simvastatin. 
Kombinacija zdravila Prevymis in ciklosporina se ne sme uporabljati z dabigatranom, atorvastatinom, pitavastatinom, rosuvastatinom in simvastatinom.
Prevymis is available as tablets to be taken by mouth and as a concentrate that is made up into a solution for infusion (drip) into a vein and given over about an hour. 
Zdravilo Prevymis je na voljo v obliki tablet, ki jih je treba zaužiti peroralno, in v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije) v veno, ki se daje približno eno uro.
Prevymis must not be used together with the medicine pimozide, or ergot medicines such as ergotamine and dihydroergotamine. 
Zdravilo Prevymis se ne sme uporabljati v kombinaciji z zdravilom pimozid ali zdravili iz rženih rožičkov, kot sta ergotamin in dihidroergotamin.
For practical information about using Prevymis, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Prevymis naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
By blocking the enzyme, the medicine prevents viruses from developing properly, so that CMV cannot multiply and infect other cells. 
Zdravilo z zaviranjem tega encima virusom preprečuje, da bi se pravilno razvijali, zato se citomegalovirus ne more pomnoževati in okužiti drugih celic.
Allogeneic haematopoietic stem cell transplantation involves using stem cells from a donor to replace the recipient's bone marrow cells to form new bone marrow that produces healthy blood cells. 
Alogenska presaditev krvotvornih matičnih celic vključuje uporabo matičnih celic darovalca za zamenjavo prejemnikovih celic kostnega mozga, da bi nastal nov kostni mozeg, ki bi proizvajal zdrave krvne celice.
Letermovir, the active substance in Prevymis, blocks a virus enzyme called ‘terminase'. 
Letermovir, zdravilna učinkovina v zdravilu Prevymis, zavira virusni encim, imenovan „terminaza“.
A main study involving 570 adults found Prevymis was more effective than placebo (a dummy treatment) in preventing CMV infection after allogeneic haematopoietic stem cell transplantation. 
V glavni študiji, v katero je bilo vključenih 570 odraslih, se je izkazalo, da je zdravilo Prevymis pri preprečevanju okužbe s citomegalovirusom po alogenski presaditvi krvotvornih matičnih celic učinkovitejše od placeba (zdravila brez zdravilne učinkovine).
How is Prevymis used? 
Kako se zdravilo Prevymis uporablja?
Treatment with Prevymis is started on the day of the transplant or on any day up to 28 days afterwards and it is continued for 100 days after the transplantation; longer treatment may be considered in some patients. 
Če se sočasno uporablja ciklosporin (zdravilo za preprečevanje zavrnitve presadka), se odmerek zdravila Prevymis zmanjša na 240 mg enkrat na dan. Zdravljenje z zdravilom Prevymis se začne na dan presaditve ali na kateri koli dan do 28 dni pozneje in se nadaljuje še 100 dni po presaditvi; pri nekaterih bolnikih je lahko potrebno daljše zdravljenje.
Prevymis can only be obtained with a prescription, and treatment should be started by a doctor experienced in managing patients who have had an allogeneic haematopoietic stem cell transplant. 
Predpisovanje in izdaja zdravila Prevymis je le na recept, zdravljenje pa mora uvesti zdravnik z izkušnjami z zdravljenjem bolnikov z alogenskim presadkom krvotvornih matičnih celic.
However, CMV can become active in patients whose immune system is weakened such as those having stem cell transplants. 
Pri bolnikih, pri katerih je imunski sistem oslabljen, npr. po presaditvi matičnih celic, pa se lahko aktivira.
This is expected to prevent CMV disease in transplant recipients who already have CMV in their body. 
To naj bi pri prejemnikih presadka, ki imajo citomegalovirus že v svojem telesu, preprečevalo okužbo zaradi njega.
Prevymis is an antiviral medicine used to prevent illness caused by cytomegalovirus (CMV) in adults having an allogeneic haematopoietic stem cell transplant to replace their bone marrow. 
Zdravilo Prevymis je protivirusno zdravilo, ki se uporablja za preprečevanje bolezni, ki jo pri odraslih s presadkom krvotvornih matičnih celic za zamenjavo kostnega mozga povzroča citomegalovirus (CMV).
For the full list of side effects reported with Prevymis, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Prevymis, glejte navodilo za uporabo.
It has few side effects unlike other medicines used for the treatment of CMV disease which can damage bone marrow and affect blood cells. 
V nasprotju z drugimi zdravili za zdravljenje okužbe s citomegalovirusom, ki lahko poškodujejo kostni mozeg in prizadenejo krvne celice, ima le malo neželenih učinkov.
How does Prevymis work? 
Kako zdravilo Prevymis deluje?
Prevymis contains the active substance letermovir. 
Zdravilo Prevymis vsebuje zdravilno učinkovino letermovir.
Prevymis is effective in preventing CMV from becoming active and causing disease in adult recipients of a stem cell transplantation to replace the bone marrow. 
Zdravilo Prevymis pri odraslih prejemnikih presadka matičnih celic za zamenjavo kostnega mozga učinkovito preprečuje, da bi se citomegalovirus aktiviral in povzročil obolenje.
Date of first authorisation: 18 September 2015 
Datum prve odobritve: 18. september 2015
See below. 
Glejte spodaj.
These measures will help protect the environment. 
Takšni ukrepi bodo pomagali varovati okolje.
A risk to newborns/infants cannot be excluded. 
Tveganja za novorojence/dojenčke ni mogoče izključiti.
Tell your doctor if you think you may have another infection. 
Zdravniku povejte, če menite, da imate drugo okužbo.
This medicine should not be given to children under 18 years old because there is not enough information on use in this age group. 
Tega zdravila se ne sme uporabljati pri otrocih, mlajših od 18 let, ker o uporabi pri tej starostni skupini ni dovolj podatkov.
The preparation for each dose is shown below. 
Priprava posameznih odmerkov je prikazana spodaj.
Modification of PBPs 
spremembo PBP-jev
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. 
Zdravila se ne sme mešati z drugimi zdravili, razen s tistimi, ki so navedena v poglavju 6.6.
The duration of treatment should follow the recommendations in Table 1. 
Glede trajanja zdravljenja je treba slediti priporočilom v preglednici 1.
Your doctor will decide on the dose that you need. 
Zdravnik bo določil, kakšen odmerek potrebujete.
From a microbiological point of view, the medicinal product should be used immediately upon reconstitution. 
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj po rekonstituciji.
1 hour 
1 ura
CAUTION: THE RECONSTITUTED SOLUTION IS NOT FOR DIRECT INJECTION. 
OPOZORILO: REKONSTITUIRANA RAZTOPINA NI ZA NEPOSREDNO INJICIRANJE.
Safety and efficacy in paediatric patients have not been established. 
Varnost in učinkovitost pri pediatričnih bolnikih nista bili dokazani.
Minimum Inhibitory Concentrations (mg/L) 
Minimalne inhibitorne koncentracije (mg/l)
Your doctor may also want to test your blood to make sure you receive an appropriate dose, especially if you have to take this medicine for a long time. 
Poleg tega vam bo zdravnik morda kontroliral tudi kri in tako preveril, da prejemate primeren odmerek zdravila, zlasti če to zdravilo prejemate dolgo časa.
The final volume is approximately 11.4 mL per vial. 
Končna količina je približno 11,4 ml na vialo.
The medicinal product is photosensitive and should be protected from light when not stored in the original carton. 
Zdravilo je občutljivo za svetlobo in ga je treba zaščititi pred svetlobo, kadar ni shranjeno v originalni škatli.
Tazobactam is a substrate for OAT1 and OAT3. 
Tazobaktam je substrat OAT1 in OAT3.
**All doses of Zerbaxa are administered intravenously over 1 hour and are recommended for all indications. 
**Vsi odmerki zdravila Zerbaxa se dajejo intravensko v teku 1 ure in so priporočeni za vse indikacije.
7 days 
7 dni
63963, Clermont Ferrand Cedex 9 France 
63963, Clermont Ferrand Cedex 9 Francija
Laboratory values 
Laboratorijske vrednosti
After reconstitution, chemical and physical in-use stability has been demonstrated for 4 days at 2 to 8°C. 
Po rekonstituciji sta kemična in fizikalna stabilnost med uporabo dokazani za 4 dni pri temperaturi od 2 °C do 8 °C.
If super infection occurs during or following treatment, appropriate measures should be taken. 
Če se med ali po zdravljenju pojavi superinfekcija, je treba ustrezno ukrepati.
Minimum inhibitory concentration breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows: 
Mejne vrednosti minimalnih inhibitornih koncentracij, ki jih je določil Evropski odbor za testiranje občutljivosti za protimikrobna zdravila (EUCAST - European Committee on Antimicrobial Susceptibility Testing), so:
The safety and efficacy of ceftolozane/tazobactam in children and adolescents below 18 years of age have not yet been established. 
Varnost in učinkovitost ceftolozana/tazobaktama pri otrocih in mladostnikih, starih manj kot 18 let, še nista bili dokazani.
The dose depends on the type of infection that you have, where the infection is in your body and how serious the infection is. 
Odmerek je odvisen od vrste okužbe in od tega, kje v telesu je okužba in kako resna je.
This leaflet was last revised in {month YYYY}. 
Navodilo je bilo nazadnje revidirano dne
Mechanisms of resistance 
Mehanizmi odpornosti
Your doctor or other healthcare professional will give you this medicine into one of your veins through an infusion (a drip) lasting one hour. 
To zdravilo vam bo dal zdravnik ali drug zdravstveni delavec v eno izmed ven z infuzijo (kapalno), ki bo trajala eno uro.
One of these 60 patients had bacteraemia at baseline. 
Eden od 60 bolnikov je imel v izhodišču bakteriemijo.
Variations in colour within this range do not affect the potency of the product. 
Razlike v barvi v tem okviru ne vplivajo na učinkovitost zdravila.
The dose of medicine given to you depends on whether or not you have kidney problems. 
Odmerek zdravila, ki ga boste prejeli, je odvisen od tega, ali imate kakšne težave z ledvicami ali ne.
Treatment with Zerbaxa sometimes causes production of antibodies that react with your red blood cells. 
Zdravljenje z zdravilom Zerbaxa včasih povzroči nastanek protiteles, ki reagirajo z rdečimi krvnimi celicami.
These include: - Probenecid (a medicine for gout). 
Med takšnimi je: - probenecid (zdravilo za protin).
Non-susceptible micro-organisms 
Neobčutljivi mikroorganizmi
Treatment with Zerbaxa normally lasts between 4 and 14 days, depending on the severity and location of the infection and on how your body responds to the treatment. 
Zdravljenje z zdravilom Zerbaxa po navadi traja od 4 do 14 dni, odvisno od tega, kako huda je okužba, kje v telesu je in kako se telo odzove na zdravljenje.
However, active substances that inhibit OAT1 or OAT3 (e.g., probenecid) may increase tazobactam plasma concentrations. 
Vendar pa lahko zdravilne učinkovine, ki zavrejo OAT1 ali OAT3 (npr. probenecid), povečajo koncentracijo tazobaktama v plazmi.
Zerbaxa should only be used during pregnancy if the expected benefit outweighs the possible risks to the pregnant woman and foetus. 
Zdravilo Zerbaxa se sme med nosečnostjo uporabiti le, če pričakovane prednosti odtehtajo možna tveganja za nosečnico in plod.
AmpC enzymes (produced by Enterobacterales) 
encimov AmpC (ki jih tvorijo Enterobacterales)
Zerbaxa is indicated for the treatment of the following infections in adults (see section 5.1): 
Zdravilo Zerbaxa je indicirano za zdravljenje naslednjih okužb (glejte poglavje 5.1) pri odraslih:
If you are pregnant or breast-feeding, or think you may be pregnant, ask your doctor or pharmacist for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči, se posvetujte z zdravnikom ali farmacevtom, preden prejmete to zdravilo.
Zerbaxa is a medicine used to treat a range of bacterial infections. 
Zdravilo Zerbaxa je zdravilo, ki se uporablja za zdravljenje različnih bakterijskih okužb.
Environmental Risk Assessment (ERA) 
Ocena tveganja za okolje
These types of infection may range in severity from mild to life-threatening. 
Resnost takšnih okužb je lahko od blage do življenjsko nevarne.
In such circumstances, the discontinuation of therapy with ceftolozane/tazobactam and the use of supportive measures together with the administration of specific treatment for Clostridioides difficile should be considered. 
V takšnih primerih je treba razmisliti o prenehanju zdravljenja s ceftolozanom/tazobaktamom in o uporabi podpornih ukrepov skupaj s specifičnim zdravljenjem okužbe s Clostridioides difficile.
Environmental risk assessment studies have shown that one of the active ingredients, ceftolozane, may pose a risk to surface water organisms (see section 6.6). 
Študije ocene tveganja za okolje so pokazale, da lahko ena od učinkovin, ceftolozan, predstavlja tveganje za organizme površinskih voda (glejte poglavje 6.6).
Tell your doctor straight away if you get these symptoms as you may need urgent medical treatment: - Sudden swelling of your lips, face, throat or tongue; a severe rash; and, swallowing or breathing problems. 
Nemudoma obvestite zdravnika, če se pojavijo naslednji simptomi, saj boste morda potrebovali nujno zdravljenje: - nenadno otekanje ustnic, obraza, žrela ali jezika, hud izpuščaj in težave s požiranjem ali dihanjem.
Direct antiglobulin test (Coombs test) seroconversion and potential risk of haemolytic anaemia 
Serokonverzija direktnega antiglobulinskega testa (Coombsov test) in možno tveganje za hemolitično anemijo
Do not take Zerbaxa - if you are allergic to ceftolozane, tazobactam or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Zerbaxa - če ste alergični na ceftolozan, tazobaktam ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
If a severe allergic reaction occurs during treatment with ceftolozane/tazobactam, the medicinal product should be discontinued and appropriate measures taken. 
Če se med zdravljenjem s ceftolozanom/tazobaktamom pojavi huda alergijska reakcija, je treba zdravljenje s tem zdravilom prekiniti in ustrezno ukrepati.
Frequency categories are derived according to the following conventions: common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) (see Table 3). 
Kategorije pogostnosti so opredeljene po naslednjem dogovoru: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100) (glejte preglednico 3).
What you need to know before you take Zerbaxa 
Kaj morate vedeti, preden boste prejeli zdravilo Zerbaxa
8-14 days 
8 do 14 dni
If you are told that you have an abnormal blood test (called Coombs test) tell your doctor that you are having or have recently had Zerbaxa. 
Če vam je zdravnik povedal, da imate nenormalen izvid laboratorijskega krvnega testa (imenovan Coombsov test), zdravniku povejte, da se zdravite oziroma ste se pred kratkim zdravili z zdravilom Zerbaxa.
If you think you have not been given a dose of Zerbaxa, tell your doctor or other healthcare professional immediately. 
Če menite, da niste prejeli odmerka zdravila Zerbaxa, to nemudoma povejte zdravniku ali drugemu zdravstvenemu delavcu.
Your doctor will advise if you should receive Zerbaxa during pregnancy. 
Zdravnik vam bo povedal, ali lahko prejemate zdravilo Zerbaxa med nosečnostjo.
- if you are allergic to medicines known as “cephalosporins”. 
- če ste alergični na zdravila, imenovana cefalosporini.
- if you have had a severe allergic reaction (e.g., severe skin peeling; swelling of the face, hands, feet, lips, tongue or throat; or difficulty swallowing or breathing) to certain other antibiotics (e.g., penicillins or carbapenems). 
- če ste kdaj imeli hudo alergijsko reakcijo (npr. hudo luščenje kože, oteklost obraza, dlani, stopal, ustnic, jezika ali žrela, oziroma težave s požiranjem ali dihanjem) na določene druge antibiotike (npr. peniciline ali karbapeneme).
Frequency Infusion time 
Pogostnost Čas infundiranja
Adverse reactions are classified according to MedDRA system organ class and frequency. 
Neželeni učinki so razvrščeni po organskih sistemih MedDRA in pogostnosti.
This can increase the time it takes for tazobactam to leave your body. 
To zdravilo lahko podaljša čas, potreben, da se tazobaktam odstrani iz telesa.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions are possible (see sections 4.3 and 4.8). 
Možne so resne preobčutljivostne (anafilaktične) reakcije, občasno s smrtnim izidom (glejte poglavji 4.3 in 4.8).
4-14 days 
4 do 14 dni
Other medicines and Zerbaxa 
Druga zdravila in zdravilo Zerbaxa
Augmented renal clearance 
Povečan ledvični očistek
Approximately 82% of all patients in the trial had APACHE II (Acute Physiology and Chronic Health Evaluation II) scores of < 10 and 2.3% had bacteraemia at baseline. 
Pri približno 82 % vseh bolnikov v preskušanju je bila ocena APACHE II (Acute Physiology and Chronic Health Evaluation II) < 10, 2,3 % bolnikov je imelo bakteriemijo v izhodišču.
The use of ceftolozane/tazobactam may promote the overgrowth of non-susceptible micro-organisms. 
Uporaba ceftolozana/tazobaktama lahko spodbudi razrast neobčutljivih mikroorganizmov.
In patients with moderate or severe renal impairment, and in patients with end stage renal disease on haemodialysis, the dose should be adjusted as listed in Table 2 (see sections 5.1 and 6.6). 
Pri bolnikih z zmerno ali hudo okvaro ledvic in bolnikih s končno odpovedjo ledvic na hemodializi je odmerek treba prilagoditi, kot je prikazano v preglednici 2 (glejte poglavji 5.1 in 6.6).
Pharmacokinetic/pharmacodynamic relationships 
Farmakokinetično/farmakodinamično razmerje
Your doctor may need to reduce the dose of Zerbaxa or decide how often Zerbaxa is given to you. 
Zdravnik vam bo morda moral zmanjšati odmerek zdravila Zerbaxa, ali presoditi, kako pogosto boste prejemali zdravilo Zerbaxa.
Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. 
V predkliničnih študijah so učinke opazili samo pri izpostavljenostih, bistveno večjih od največje izpostavljenosti pri človeku, kar kaže na majhen pomen za klinično uporabo.
What Zerbaxa is and what it is used for 
Kaj je zdravilo Zerbaxa in za kaj ga uporabljamo
For intravenous use after reconstitution and dilution. 
Za intravensko uporabo po rekonstituciji in redčenju.
The time above a threshold concentration has been determined to be the parameter that best predicts the efficacy of tazobactam in in vitro and in vivo non-clinical models. 
Čas nad mejno vrednostjo koncentracije se je izkazal kot parameter, ki najbolje napove učinkovitost tazobaktama v nekliničnih modelih in vitro in in vivo.
More than 80% of tazobactam was excreted as the parent compound with the remaining amount excreted as the tazobactam M1 metabolite. 
Več kot 80 % tazobaktama se je izločilo v obliki matične spojine, preostala količina pa kot presnovek tazobaktama M1.
One of the active ingredients, ceftolozane, may have harmful effects if it reaches the aquatic environment. 
Ena od učinkovin, ceftolozan, ima lahko škodljiv učinek, če pride v vodno okolje.
In the clinically evaluable (CE) patients, the clinical cure rates for ceftolozane/tazobactam were 95.9% in 293 patients aged less than 65 years and 87.8% in 82 patients aged 65 years or more. 
Pri klinično ocenljivih bolnikih je bila stopnja klinične ozdravitve za ceftolozan/tazobaktam 95,9 % pri 293 bolnikih, starih manj kot 65 let, in 87,8 % pri bolnikih, starih 65 let ali več.
Pharmacotherapeutic group: Antibacterials for systemic use, other cephalosporins and penems, ATC code: J01DI54. 
Farmakoterapevtska skupina: Zdravila za sistemsko zdravljenje bakterijskih infekcij, drugi cefalosporini in penemi, oznaka ATC: J01DI54
There is no experience with overdose of Zerbaxa. 
Izkušenj s prevelikim odmerjanjem zdravila Zerbaxa ni.
1, abdominal distension dyspepsia 
1, abdominalna distenzija
Mechanisms of bacterial resistance to ceftolozane/tazobactam include: i. 
Mehanizem bakterijske odpornosti proti ceftolozanu/tazobaktamu vključuje: i.
In vitro data indicate that the following species are not susceptible to ceftolozane/tazobactam: Staphylococcus aureus 
Podatki in vitro kažejo, da naslednje vrste niso občutljive na ceftolozan/tazobaktam: Staphylococcus aureus